temozolomide has been researched along with betadex in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Afjei, R; Babikir, HA; Bose, RJC; Chang, E; Gambhir, SS; Habte, F; Malhotra, M; Massoud, TF; Paulmurugan, R; Robinson, E; Sinclair, R; Sukumar, UK; Zeng, Y | 1 |
Bienemann, A; Bouzinab, K; Bradshaw, TD; Coyle, B; Gershkovich, P; Heravi Shargh, V; Lowis, S; Luckett, J; Paisey, S; Singleton, WGB; Stevens, MFG; Turyanska, L | 1 |
2 other study(ies) available for temozolomide and betadex
Article | Year |
---|---|
Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
Topics: Animals; beta-Cyclodextrins; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Drug Resistance, Neoplasm; Ferric Compounds; Glioblastoma; Gold; Humans; Mice; MicroRNAs; Temozolomide; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2019 |
Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; beta-Cyclodextrins; Cell Line, Tumor; Drug Carriers; Glioma; Humans; Liposomes; Male; Nanoparticles; Rats, Wistar; Spheroids, Cellular; Temozolomide | 2021 |